EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate

If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

Dewpoint Therapeutics selects groundbreaking MYC development candidate

MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence